Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant camrelizumab plus nab-paclitaxel and cisplatin for locally advanced oral squamous cell carcinoma
ChiCTR2200066119Phase 2Completed
- Sponsor
- West China Hospital of Sichuan University
- Start
- Dec 2022
- Modality
- Small Molecules, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab, paclitaxel and cisplatin in Oral Mucosal Carcinoma, sponsored by West China Hospital of Sichuan University. Primary endpoints: Major pathological response and Safety. Started Dec 2022; status: completed.
02
Drugs
camrelizumabpaclitaxelcisplatin
03
Conditions
Oral Mucosal Carcinoma
Beyond the preview
Go deeper on ChiCTR2200066119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066119.